OptimalDosages.com publishes reference material for laboratory and educational use. Nothing here is medical advice, a prescription, or a recommendation for human administration.
By continuing you confirm you are 21 or older and that you are accessing this material in a research or educational capacity.
CJC-1295 with drug affinity complex. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Low reported | 1 mg | once weekly | 0.25 mL | 25 u | 2 doses | |
| Standard | 2 mg | once weekly | 0.5 mL | 50 u | 1 doses | |
| Trial dose | 30–60 mcg/kg | weekly | Set by body weight — can't be turned into a single amount to draw | |||
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial | |
|---|---|---|---|---|---|---|
| Weeks 1–4 | 1 mg | once weekly | 0.25 mL | 25 u | 4 | 4 mg |
| Week 5 onward per 4 weeks from here on |
2 mg | once weekly | 0.5 mL | 50 u | 4 | 8 mg |
GHRH analogue conjugated to bind serum albumin, extending half-life from minutes to days. This produces sustained GH/IGF-1 elevation rather than pulses — a meaningfully different physiological profile from the no-DAC version.
Buy CJC-1295 DACthis peptideOpens optimal-pep.com in a new tab
Browse the full catalogue, or jump to a neighbouring compound.
A tetra-substituted GHRH(1-29) analogue without the drug affinity complex, giving a short pulse rather than sustained elevation. F…
The natural GHRH 1-29 fragment. Previously an approved agent for paediatric GH deficiency diagnosis and treatment before withdrawa…
Every compound compared in one table: dose range, how often, half-life and evidence tier.